Podcast

Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer

Author(s):

Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.

Welcome to OncLiveOn Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. 

In today’s episode, we had the pleasure of speaking with Hiba Khan, MD, MPH, and Natasha Kwendakwema, MD, about the effects of adverse financial events in patients with cancer. Drs Khan and Kwendakwema are hematology/oncology fellows at Fred Hutch Cancer Center in Seattle, Washington.

At the 2023 ASCO Annual Meeting, Dr Khan presented research findings regarding the risk of early mortality in patients with cancer who experience financial toxicity. This study found that patients in the Surveillance, Epidemiology, and End Results cancer registry who experienced adverse financial events between 2013 and 2018 had higher rates of early mortality compared with patients who did not experience these events. Dr Kwendakwema presented research on the effects of financial toxicity on treatment costs and healthcare utilization at the end of life for patients with cancer. This research demonstrated that patients who experienced adverse financial events were more likely to require increased end-of-life care, such as hospitalization, and more likely toincurhigher health care costs in their last 6 months of life.

In our exclusive interview, Drs Khan and Kwendakwema discussed the methods and design of these studies, the future implications of these findings, and the importance of continued investigation into the effects of financial toxicity in patients with cancer.

___

That’s all we have for today! Thank you for listening to this episode of OncLiveOn Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. 

OncLive® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. 

If you liked today’s episode of OncLiveOn Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLiveOn Air®

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn. 

Related Videos
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP
Mazyar Shadman, MD, MPH
Carmen Guerra, MD, MSCE, FACP
Rahul Banerjee, MD, FACP
Andrew Hantel, MD
Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.